INS and Hypoglycemia: The sameapplies to biosimilars for long-acting insulin analogues given the increasing use oflong-acting insulin analogues to reduce rates of hypoglycaemia amonginsulin-dependent diabetic patients, which can account for up to 30% or more ofpatients with diabetes, and the increasing cost of care of diabeticpatients.23, , , –27 Consequently, the objectivesfor this study were to assess the availability and use of biological medicines,including biosimilars, within B&H and use the findings to provide futureguidance to the authorities in B&H and wider.